Boston, MA -- (SBWIRE) -- 07/21/2014 -- VistaGen Therapeutics, Inc. (VistaGen) is a biopharmaceutical company. The company develops stem cell technology platform based on the controlled differentiation of human pluripotent stem cells. Its products include Cardiosafe 3D, Liversafe 3D, and av-101. VistaGen's stem cell technology is used to create novel bioassay systems for predictive toxicology, drug discovery, drug rescue, and cell therapy applications. The company's cardiosafe 3D product is a novel bioassay system that uses mature human heart cells derived from pluripotent stem cells to screen for heart toxicity in connection with its drug rescue activities. VistaGen is headquartered in San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
View Full Report Details and Table of Contents
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company VistaGen Therapeutics , Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Medical Devices research reports at Fast Market Research
You may also be interested in these related reports:
- Cytori Therapeutics, Inc. (CYTX) - Product Pipeline Analysis, 2014 Update
- BioMimetic Therapeutics, Inc. - Product Pipeline Analysis, 2014 Update
- Anika Therapeutics, Inc. (ANIK) - Product Pipeline Analysis, 2013 Update
- ImmunoCellular Therapeutics, Ltd. (IMUC) - Product Pipeline Analysis, 2013 Update
- InVivo Therapeutics Corporation - Product Pipeline Analysis, 2013 Update
- VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014
- Sickle Cell Disease - Pipeline Review, H1 2014
- Cancer Pain - Pipeline Review, H1 2014
- Hyperlipidemia - Pipeline Review, H1 2014
- Mantle Cell Lymphoma - Pipeline Review, H1 2014